Author

Kun Nie

Institutions: Fujian Medical University, First Affiliated Hospital of Fujian Medical University

Observed institutions: Fujian Medical University, First Affiliated Hospital of Fujian Medical University, Kura Oncology (United States)

ORCID: 0000-0002-9632-3183

Observed ORCID: 0000-0002-9632-3183

OpenAlex ID: A5049010089

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

2024 · Eunice S Wang, Ghayas C Issa, et al. · The Lancet Oncology · 119

Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia

2023 · Aaron D. Goldberg, Daniel Corum, et al. · Blood · 16

P504: Updated Data for Ziftomenib in Patients With Npm1-mutated Relapsed or Refractory Acute Myeloid Leukemia

2023 · Amir Fathi, Eunice Wang, et al. · HemaSphere · 14

AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

2023 · Harry Erba, Eunice Wang, et al. · Clinical Lymphoma Myeloma & Leukemia · 9

A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma.

2022 · Glenn J. Hanna, Cesar Augusto Perez, et al. · Journal of Clinical Oncology · 5

Arachidonic Acid Disrupts PKM2 ‐Linked Glycolysis‐Related Metabolism and Exacerbates PAN ‐Induced Podocyte Injury

2026 · Kun Nie, Xiaowei Gao, et al. · Journal of Cellular and Molecular Medicine

Clinical and Pathological Characteristics and Prognosis of Diabetic Nephropathy Patients With Tertiary Lymphoid Structures

2025 · Yongjie Zhuo, Mengjie Weng, et al. · Journal of Diabetes Research

POSTER: AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

2023 · Harry Erba, Eunice Wang, et al. · Clinical Lymphoma Myeloma & Leukemia

Abstract CT253: A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial)

2022 · Glenn J. Hanna, Cesar Perez Batista, et al. · Cancer Research

Works count: 9

Citation count: 163

H-index: 5

I10-index: 3